News Stocks Brooks Laboratories Limited Receives ITAT Orders Dismissing Appeals for Assessment Years 2012-13, 2014-15 and 2016-17Brooks Laboratories Limited Receives ITAT Orders Dismissing Appeals for Assessment Years 2012-13, 2014-15 and 2016-17
Brooks Laboratories Limited disclosed that the Income Tax Appellate Tribunal (ITAT) Chandigarh Bench dismissed the company's appeals for Assessment Years 2012-13, 2014-15 and 2016-17. The appeals were filed against orders from the Commissioner of Income Tax (Appeals) and National Faceless Appeal Centre, where the company had received partial relief. Despite the dismissal, Brooks Laboratories stated there is no material impact on its financials, operations, or other business activities.
*this image is generated using AI for illustrative purposes only.
Brooks Laboratories Limited has disclosed to stock exchanges that the Income Tax Appellate Tribunal (ITAT) has passed orders dismissing the company's appeals for multiple assessment years. The pharmaceutical company made this disclosure under Regulation 30 of the SEBI Listing Regulations on January 30, 2026.
ITAT Orders and Assessment Years
The Income Tax Appellate Tribunal, Chandigarh Bench, dismissed appeals filed by Brooks Laboratories for three specific assessment years. The company downloaded these orders from the ITAT online portal on January 30, 2026.
| Assessment Year: | Status |
|---|---|
| 2012-13 | Appeal Dismissed |
| 2014-15 | Appeal Dismissed |
| 2016-17 | Appeal Dismissed |
Background of Appeals
The company had originally filed these appeals against orders passed by the Commissioner of Income Tax (Appeals) and National Faceless Appeal Centre. In those earlier proceedings, Brooks Laboratories received partial relief while certain additions and disallowances were upheld by the tax authorities.
The ITAT has now upheld the orders of the Commissioner of Income Tax (Appeals) on all contested issues, resulting in the dismissal of the company's appeals for all three assessment years.
Financial and Operational Impact
Despite the unfavorable outcome of the appeals, Brooks Laboratories has assessed the impact on its business operations. The company has explicitly stated in its regulatory filing that there is no material impact on the financials, operations, or other activities of the company.
| Impact Area: | Assessment |
|---|---|
| Financial Impact | No material impact |
| Operational Impact | No impact |
| Other Activities | No impact |
Regulatory Compliance
The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company provided detailed information as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, ensuring full compliance with regulatory requirements for material event disclosures.
Historical Stock Returns for Brooks Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.57% | -8.22% | -20.86% | -58.41% | -58.37% | -0.89% |
17
